Organic nitrates in cardiovascular disease

Cellular and Molecular Biology

Volumn 51, Issue 3, 2005, Pages 307-320

  Bode Boger S M ^a   Kojda, G ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Coronary artery disease; Heart failure; L arginin; Nicorandil; Nitrates

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CROMAKALIM; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE INHIBITOR; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LISINOPRIL; LOSARTAN; MOLSIDOMINE; NICORANDIL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; ORGANIC NITRATE; PENTAERYTHRITYL TETRANITRATE; PRAVASTATIN; PRAZOSIN; RAMIPRIL; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEART FAILURE; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTERY DILATATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLLAPSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENDOTHELIAL DYSFUNCTION; EXFOLIATIVE DERMATITIS; FLUSHING; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEARTBURN; HEMODYNAMICS; HUMAN; HYPOTENSION; NAUSEA; NONHUMAN; PALLIATIVE THERAPY; PHYSICAL ACTIVITY; RASH; REDUCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; SURVIVAL; SYNCOPE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VEIN DILATATION; VOMITING;

ANGINA, UNSTABLE; ANIMALS; CARDIOVASCULAR DISEASES; CYCLIC GMP; ENALAPRIL; ENDOTHELIUM, VASCULAR; HEMODYNAMIC PROCESSES; HUMANS; MYOCARDIAL INFARCTION; NITRATES; NITRIC OXIDE; NITROGLYCERIN; PLATELET AGGREGATION;

ANIMALIA;

EID: 30744436084     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Pas d'auteur ? = OK si c'est une enquete, un rapport? Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [see comments]. Lancet 1994, 344: 1383-1389.
2. Abou-Mohamed, G., Johnson, J.A., Jin, L., El Remessy A.B., Do, K., Kaesemeyer, W.H., Caldwell, R.B. and Caldwell, R.W., Roles of superoxide, peroxynitrite, and protein kinase C in the development of tolerance to nitroglycerin. J Pharmacol. Exp. Ther. 2004, 308: 289-299.
3. Abou-Mohamed, G., Kaesemeyer, W.H., Caldwell, R.B. and Caldwell, R.W., Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br. J. Pharmacol. 2000, 130: 211-218.
4. Abrams, J., The role of nitrates in coronary heart disease. Arch. Intern. Med. 1995, 155: 357-364.
5. Adams, M.R., McCredie, R., Jessup, W., Robinson, J., Sullivan, D. and Celermajer, D.S., Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997, 129: 261-269.
6. Ahlner, J., Andersson, R.G.G., Torfgård, K. and Axelsson, K.L., Organic nitrate esters: Clinical use and mechanisms of actions. Pharmacol. Rev. 1991, 43: 351-423.
7. Badesch, D.B., Abman, S.H., Ahearn, G.S., Barst, R.J., McCrory, D.C., Simonneau, G and McLaughlin, V.V., Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2004, 126: 35S-62S.
8. Bassenge, E. and Stuart, D.J., Effects of nitrates in various vascular sections and regions. Z. Kardiol. 1986, 75 (Suppl. 3): 1-7.
9. Bennett, B.M., McDonald, B.J. and St.James, M.J., Hepatic cytochrome P-450-mediated activation of rat aortic guanylyl cyclase by glyceryl trinitrate. J. Pharmacol. Exp. Ther. 1992, 261: 716-723.
10. Bloche, M.G., Race-based therapeutics. N. Engl. J. Med. 2004, 351: 2035-2037.
11. Blum, A., Hathaway, L., Mincemoyer, R., Schenke, W.H., Kirby M., Csako, G., Waclawiw, M.A., Panza, J.A. and Cannon, R.O., III, Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000, 101: 2160-2164.
12. Bode-Boger, S.M., Boger, R.H., Galland, A., Tsikas, D. and Frolich, J.C., L-arginine-induced vasodilation in healthy humans: pharmacokinetic- pharmacodynamic relationship. Br. J. Clin. Pharmacol. 1998, 46: 489-497.
13. Bode-Boger, S.M., Boger, R.H., Loffler, M., Tsikas, D., Brabant, G. and Frolich, J.C., L-arginine stimulates NO-dependent vasodilation in healthy humans - effect of somatostatin pretreatment. J. Investig. Med. 1999, 47: 43-50.
14. Bode-Boger, S.M., Muke, J., Surdacki, A., Brabant, G., Boger, R.H. and Frolich, J.C., Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc. Med. 2003, 8: 77-81.
15. Boesgaard, S., Aldershvile, J., Poulsen, H.E., Loft, S., Andersen, M.E. and Meister, A., Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ. Res. 1994, 74: 115-120.
16. Böger, R.H. and Bode-Böger, S.M., The clinical pharmacology of L-arginine. Annu. Rev. Pharmacol. Toxicol. 2001, 41: 79-99.
17. Bolli, R., Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J. Mol. Cell. Cardiol. 2001, 33: 1897-1918.
18. Brien, J.F., McLaughlin, B.E., Breedon, T.H., Bennett, B.M., Nakatsu, K. and Marks, G.S., Biotransformation of GTN occurs concurrently with relaxation of rabbit aorta. J. Pharmacol. Exp. Ther. 1986, 237: 608-614.
19. Ceremuzynski, L., Chamiec, T. and Herbaczynska-Cedro, K., Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am. J. Cardiol. 1997, 80: 331-333.
20. Chen, Z., Zhang, J. and Stamler, J.S., Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc. Natl. Acad. Sci. USA 2002, 99: 8306-8311.
21. Chin-Dusting, J.P.F., Kaye, D.M., Lefkovits, J., Wong, J., Bergin, P. and Jennings, G.L., Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J. Am. Coll. Cardiol. 1996, 27: 1207-1213.
22. Chrysant, S.G., Glasser, S.P., Bittar, N., Shahidi, F.E., Danisa, K., Ibrahim, R., Watts, L.E., Garutti, R.J., Ferraresi, R. and Casareto, R., Efficacy and safety of extended-release Isosorbide mononitrate for stable effort angina pectoris. Am. J. Cardiol. 1993, 72: 1249-1256.
23. Cohn, J.N., The management of chronic heart failure. N. Engl. J. Med. 1996, 335: 490-498.
24. Cohn, J.N., Archibald, D.G., Ziesche, S., Fraciosa, J.A., Harston, W.E., Tristani, F.E., Dunkman, W.B., Jacobs, W., Francis, G.S., Flohr, K.H. and et al., Effect of vasodilator therapy on mortality in chronic congestive heart failure. N. Engl. J. Med. 1986, 314: 1547-1552.
25. Cohn, J.N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W.B., Loeb, H., Wong, M., Bhat, G., Goldman, S., Fletcher, R.D., Doherty J., Hughes, C.V., Carson, P., Cintron, G., Shabetai, R. and Haakenson, C., A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 1991, 325: 303-310.
26. Cooke, J.P., Singer, A.H., Tsao, P., Zera, P., Rowan, R.A. and Billingham, M.E., Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 1992, 90: 1168-1172.
27. De Caterina, R., Giannessi, D., Crea, F., Chiercha, S., Bernini, W., Gazzetti, P. and L'Abbate, A., Inhibition of platelet function by injectable isosorbide dinitrate. Am. J. Cardiol. 1984, 53: 1683-1687.
28. De la Lande, I.S., Stafford, I. and Horowitz, J.D., Tolerance induction by transdermal glyceryl trinitrate in rats. Eur. J. Pharmacol. 1999, 374: 71-75.
29. Del Soldato, P., Sorrentino, R. and Pinto, A., NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci. 1999, 20: 319-323.
30. DeMots, H. and Glasser, S.P., Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable anginao. J. Am. Coll. Cardiol. 1989, 13: 786-795.
31. DiFabio, J., Ji, Y., Vasiliou, V., Thatcher, G.R. and Bennett, B.M., Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol. Pharmacol. 2003, 64: 1109-1116.
32. Diodati, J., Théroux, P., Latour, J.G., Lacoste, L., Lam, J.Y.T. and Waters, D., Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. Am. J. Cardiol. 1990, 66: 683-688.
33. Diodati, J.G., Cannon, R.O., III, Hussain, N. and Quyyumi, A.A., Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. Am. J. Cardiol. 1995, 75: 443-448.
34. Ekbom, K., Sjostrand, C., Svensson, D.A. and Waldenlind, E., Periods of cluster headache induced by nitrate therapy and spontaneous remission of angina pectoris during active clusters. Cephalalgia 2004, 24: 92-98.
35. Filippov, G., Bloch, D.B. and Bloch, K.D., Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J. Clin. Invest. 1997, 100: 942-948.
36. Fiorucci, S., Santucci, L., Gresele, P., Faccino, R.M., Del Soldato, P. and Morelli, A., Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003, 124: 600-607.
37. Freeman, J.G., Barton, J.R. and Record, C.O., Effect of isosorbide dinitrate, verapamil and labetalol on portal pressure in cirrhosis. Br. Med. J. 1985, 291: 561-562.
38. Friebe, A. and Koesling, D., Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. 1998, 53: 123-127.
39. Friebe, A., Schultz, G. and Koesling, D., Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 1996, 15: 6863-6868.
40. Gaine, S., Pulmonary hypertension. JAMA 2000, 284: 3160-3168.
41. Gewaltig, M.T. and Kojda, G., Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc. Res. 2002, 55: 250-260.
42. Glasser, S.P., Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. IMDUR Study Group. Am. J. Cardiol. 1997, 80: 1546-1550.
43. Göbel, E.J.A.M., Hautvast, R.W.M., Van Gilst, W.H., Spanjaard, J.N., Hillege, H.L., DeJongste, M.J.L., Molhoek, G.P. and Lie, K.I., Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. Lancet 1995, 346: 1653-1657.
44. Gori, T., Burstein, J.M., Ahmed, S., Miner, S.E., Al Hesayen, A., Kelly S. and Parker, J.D., Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001, 104: 1119-1123.
45. Gruetter, C.A. and Lemke, S.L., Dissociation of cystein and glutathione levels from nitroglycerin induced relaxation. Eur. J. Pharmacol. 1985, 111: 85-92.
46. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994, 343: 1115-1122.
47. Hacker, A., Müller, S., Meyer, W. and Kojda, G., The Nitric Oxide Donor Pentaerythritol Tetranitrate Can Preserve Endothelial Function in Established Atherosclerosis. Br. J. Pharmacol. 2001, 132: 1707-1714.
48. Hambrecht, R., Hilbrich, L., Erbs, S., Gielen, S., Fiehn, E., Schoene, N. and Schuler, G., Correction of endothelial dysfunction in chronic heart failure: Additional effects of exercise training and oral L-arginine supplementation. J. Am. Coll. Cardiol. 2000, 35: 706-713.
49. Harrison, D.G., [Endogenous and therapeutic nitrates in healthy and arteriosclerotic blood vessels]. Schweiz Rundsch Med. Prax. 1993, 82: 1172-1176.
50. Hennekens, C.H., Albert, C.M., Godfried, S.L., Gaziano, J.M. and Buring, J.E., Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N. Engl. J. Med. 1996, 335: 1660-1667.
51. Hennekens, C.H., Buring, J.E., Sandercock, P., Collins, R. and Peto, R., Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989, 80: 749-756.
52. Hoeper, M.M., Rrowka, M.J. and Strassburg, C.P., Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004, 363: 1461-1468.
53. Huang, A., Sun, D., Shesely E.G., Levee, E.M., Koller, A. and Kaley, G., Neuronal NOS-dependent dilation to flow in coronary arteries of male eNOS-KO mice. Am. J. Physiol. Heart Circ. Physiol. 2002, 282: H429-H436.
54. Hunt, S.A., Baker, D.W., Chin, M.H., Cinquegrani, M.P., Feldman, A.M., Francis, G.S., Ganiats, T.G., Goldstein, S., Gregoratos, G., Jessup, M.L., Noble, R.J., Packer, M., Silver, M.A., Stevenson, L.W., Gibbons, R.J., Antman, E.M., Alpert, J.S., Faxon, D.P., Fuster, V., Jacobs, A.K., Hiratzka, L.F., Russell, R.O. and Smith, S.C., Jr., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 2001, 38: 2101-2113.
55. ISIS-1-Investigators, Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986, 2: 57-66.
56. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2(8607): 349-360.
57. ISIS-4 Collaborative Group, ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995, 345: 669-685.
58. Jaffrani, N.A., Ehrenpreis, S., Laddu, A. and Somberg, J., Therapeutic approach to unstable angina: Nitroglycerin, heparin, and combined therapy. Am. Heart J. 1993, 126: 1239-1242.
59. Jugdutt, B.I., Effect of nitrates on myocardial remodeling after acute myocardial infarction. Am. J. Cardiol. 1996, 77: 17C-23C.
60. Karlberg, K.E., Saldeen, T., Wallin, R., Henriksson, P., Nyquist, O. and Sylvén, C., Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: a double-blind placebo-controlled study. J. Intern. Med. 1998, 243: 25-31.
61. Kerins D.M., Robertson R.M., Robertson D. Drugs used for the treatment of myocardial ischemia. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, Hardman J.G., Limbird L.E. (eds.), McGraw-Hill, New York, 2001, pp. 843-870.
62. Kim, D., Rybalkin, S.D., Pi, X., Wang, Y., Zhang, C., Munzel, T., Beavo, J.A., Berk, B.C. and Yan, C., Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 2001, 104: 2338-2343.
63. Kiraly C., Kiss, A., Timar, S., Kristof, E., Hegedus, I. and Edes, I., Effects of long-term transdermal nitrate treatment on left ventricular function in patients following myocardial infarction. Clin. Cardiol. 2003, 26: 120-126.
64. Ko, F.-N., Wu, C.-C., Kuo, S.-C., Lee, F.-Y. and Teng, C.-M., YC-1, a novel activator of platelet guanylate cyclase. Blood 1994, 84: 4226-4233.
65. Kojda G. Therapeutic importance of nitrovasodilators. In: Handbook of Pharmacology, Vol. 143: Nitric Oxide,Mayer B. (ed.), Springer Verlag, Berlin, New-York, Tokyo, 2000, pp. 365-384.
66. Kojda, G., Role of nicorandil in ischaemic preconditioning. Lancet 2002, 360: 1889.
67. Kojda, G. and Kottenberg, K., Regulation of basal myocardial function by NO. Cardiovasc. Res. 1999, 41: 514-523.
68. Kojda, G., Meyer, W. and Noack, E., Influence of endothelium and nitrovasodilators on free thiols and disulfides in porcine coronary smooth muscle. Eur. J. Pharmacol. 1993, 250: 385-394.
69. Kojda, G., Patzner, M., Hacker, A. and Noack, E., Nitric oxide inhibits vascular bioactivation of glyceryl trinitrate. A novel mechanism to explain preferential venodilation of organic nitrates. Mol. Pharmacol. 1998, 53: 547-554.
70. Kukovetz, W.R. and Holzmann, S., Cyclic GMP in nicorandil-induced vasodilatation and tolerance development. J. Cardiovasc. Pharmacol. 1987, 10(Suppl 8): S25-30.
71. Kurz, S., Hink, U., Nickenig, G., Borthayre, A.B., Harrison, D.G. and Munzel, T., Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation 1999, 99: 3181-3187.
72. Laursen, J.B., Mülsch, A., Boesgaard, S., Mordvintcev, P., Trautner, S., Gruhn, N., Nielsen-Kudsk, J.E., Busse, R. and Aldershvile, J., In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide. Circulation 1996, 94: 2241-2247.
73. Levacher, S., Letoumelin, P., Pateron, D., Blaise, M., Lapandry C. and Pourriat, J.L., Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995, 346: 865-868.
74. Lowson, S.M., Inhaled alternatives to nitric oxide. Anesthesiology 2002, 96: 1504-1513.
75. Lüscher, T.F., Diedrich, D., Siebenmann, R., Lehmann, K. and Stülz, P., Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N. Engl. J. Med. 1988, 319: 462-467.
76. Mahmarian, J.J., Moyé, L.A., Chinoy DA., Sequeira, R.F., Habib, G.B., Henry, W.J., Jain, A., Chaitman, B.R., Weng, C.S.W., Morales-Ballejo, H. and Pratt, C.M., Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction - Results of a multicenter prospective randomized, double-blind, placebo-controlled trial. Circulation 1998, 97: 2017-2024.
77. Majid, P.A., DeFeyter, P.J., Van der Wall, E.E., Warden, R. and Roos, J.P., Molsidomine in the treatment of patients with angina pectoris. N. Engl. J. Med. 1980, 302: 1-6.
78. Martens, D. and Kojda, G., Impaired Vasodilator Response to Organic Nitrates in Isolated Basilar Arteries. Br. J. Pharmacol. 2001, 132: 30-36.
79. Merkel, C., Gatta, A., Donada, C., Enzo, E., Marin, R., Amodio, P., Torboli, P., Angeli, P., Cavallarin, G., Sebastianelli, G., Susanna, S., Mazzaro, C., Beltrame, P., Bartoli, G., Borsato, L., Caruso, N., Cielo, R., Dabroi, L., DeVenuto, G., Donadon, V., Spandri, P., Bellumat, A., Brosolo, P. and Caregaro, L., Long-term effect of nadolol or nadolol plus isosorbide-5- mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology 1995, 22: 808-813.
80. Milone, S.D., Azevedo, E.R., Forster, C. and Parker, J.D., The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin. J. Cardiovasc. Pharmacol. 1999, 34: 645-650.
81. Moncada, S., Rees, D.D., Schulz, R. and Palmer, R.M.J., Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc. Natl. Acad. Sci. USA 1991, 88: 2166-2170.
82. Muller, S., Konig, I., Meyer, W. and Kojda, G., Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate. J. Am. Coll. Cardiol. 2004, 44: 624-631.
83. Muller, S., Laber, U., Mullenheim, J., Meyer, W. and Kojda, G., Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance. J. Am. Coll. Cardiol. 2003, 41: 1994-2000.
84. Mülsch, A., Mordvintcev, P., Bassenge, E., Jung, F., Clement, B. and Busse, R., In vivo spin trapping of glyceryl trinitrate-derived nitric oxide in rabbit blood vessels and organs. Circulation 1995, 92: 1876-1882.
85. Münzel, T. and Harrison, D.G., Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance. J. Mol. Med. 1997, 75: 891-900.
86. Münzel, T., Kurz, S., Rajagopalan, S., Bennington, W., Thompson, A., Freeman, B. and Harrison, D., Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J. Clin. Invest. 1996, 98: 1465-1470.
87. Murrel, W., Nitro-glycerine as a remedy for angina pectoris. Lancet 1879, 1: 80-81.
88. Muscara, M.N., Lovren, F., McKnight, W., Dicay M., Del Soldato, P., Triggle, C.R. and Wallace, J.L., Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br. J. Pharmacol. 2001, 133: 1314-1322.
89. Nakamura, Y., Moss, A.J., Brown, M.W., Kinoshita, M., Kawai, C. and Multictr Myocardial Ischemia Res Grp, Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Am. Heart J. 1999, 138: 577-585.
90. Napoli, C., Ackah, E., De Nigris, F., Del Soldato, P., D'Armiento, F.P., Crimi, E., Condorelli, M. and Sessa, W.C., Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. USA 2002, 99: 12467-12470.
91. Napoli, C., Cirino, G., Del Soldato, P., Sorrentino, R., Sica, V., Condorelli, M., Pinto, A. and Ignarro, L.J., Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. USA 2001, 98: 2860-2864.
92. Needleman, P. and Johnson, E.M., Mechanism of tolerance development to organic nitrates. J. Pharmacol. Exp. Ther. 1973, 184: 709-713.
93. Olesen, J., Thomsen, L.L. and Iversen, H., Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol. Sci. 1994, 15: 149-153.
94. Parker, J.D. and Gori, T., Tolerance to the organic nitrates: new ideas, new mechanisms, continued mystery. Circulation 2001, 104: 2263-2265.
95. Parker, J.D., Parker, A.B., Farrell, B. and Parker, J.O., Intermittent transdermal nitroglycerin therapy: Decreased anginal threshold during the nitrate-free interval. Circulation 1995, 91: 973-978.
96. Parker, J.D. and Parker, J.O., Nitrate therapy for stable angina pectoris. N. Engl. J. Med. 1998, 338: 520-531.
97. Parker, J.O., Farrell, B., Lahey K.A. and Moe, G., Effects of intervals between doses on the development of tolerance to isosorbide dinitrate. N. Engl. J. Med. 1987, 316: 1440-1444.
98. Parker, J.O., Isosorbide-5-Mononitrate Study Group, Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am. J. Cardiol. 1993, 72: 871-876.
99. Parker, J.O., Parker, J.D., Caldwell, R.W., Farrell, B. and Kaesemeyer, W.H., The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J. Am. Coll. Cardiol. 2002, 39: 1199-1203.
100. Physicians' Health Study Research Group, Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med. 1989, 321: 129-135.
101. Pitt, B., Byington, R.P., Furberg, C.D., Hunninghake, D.B., Mancini, G.B., Miller, M.E. and Riley, W., Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000, 102: 1503-1510.
102. Preckel, B., Kojda, G., Schlack, W., Ebel, D., Kottenberg, K. and Thämer, V., Organic nitrates and spontaneous NO-donors offer positive inotropic effects in the dog heart in vivo. Acta Anaesthesiol. Scand. 1996, 40: 255-256.
103. Purcell, H., Mulcahy, D. and Fox, K., Nitrates in silent ischemia. Cardiovasc. Drugs Ther. 1994, 8: 727-734.
104. Rector, T.S., Bank, A.J., Mullen, K.A., Tschumperlin, L.K., Sih, R., Pillai, K. and Kubo, S.H., Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996, 93: 2135-2141.
105. Rossoni, G., Berti, M., Colonna, V.D., Bernareggi, M., Del Soldato, P. and Berti, F., Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit. Ital. Heart J. 2000, 1: 146-155.
106. Rubin, L.J., Executive Summary: Diagnosis and Management of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2004, 126: 4S-6S.
107. Runo, J.R. and Loyd, J.E., Primary pulmonary hypertension. Lancet 2003, 361: 1533-1544.
108. Sage, P.R., de, I.L., I, Stafford, I., Bennett, C.L., Phillipov, G., Stubberfield, J. and Horowitz, J.D., Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 2000, 102: 2810-2815.
109. Salvemini, D., Currie, M.G. and Mollace, V., Nitric oxide-mediated cyclooxygenase activation - A key event in the antiplatelet effects of nitrovasodilators. J. Clin. Invest. 1996, 97: 2562-2568.
110. Sellke, F.W., Myers, P.R., Bates, J.N. and Harrison, D.G., Influence of vessel size on the sensitivity of porcine microvessels to nitroglycerin. Am. J. Physiol. 1990, 258: H515-H520369.
111. Sellke, F.W., Tomanek, R.J. and Harrison, D.G., L-cysteine selectively potentiates nitroglycerin-induced dilation of small coronary microvessels. J. Pharmacol. Exp. Ther. 1991, 258: 365-369.
112. Shell, W.E., Kivowitz, C.F., Rubins, S.B. and See, J., Mechanisms and therapy of silent myocardial ischemia: The effect of transdermal nitroglycerin. Am. Heart J. 1986, 112: 222-229.
113. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H. and Packard, C.J., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group [see comments]. N. Engl. J. Med. 1995, 333: 1301-1307.
114. Silber, S., Vogler, A.C., Krause, K.H., Vogel, M. and Theisen, K., Induction and circumvention of nitrate tolerance applying different dosage intervals. Am. J. Med. 1987, 83: 860-870.
115. Stamler, J.S. and Loscalzo, J., The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. J. Am. Coll. Cardiol 1991, 18: 1529-1536.
116. Stasch, J.P., Becker, E.M., Alonso-Alija, C., Apeler, H., Dembowsky K., Feurer, A., Gerzer, R., Minuth, T., Perzborn, E., Pleiss, U., Schroder, H., Schroeder, W., Stahl, E., Steinke, W., Straub, A. and Schramm, M., NO-independent regulatory site on soluble guanylate cyclase. Nature 2001, 410: 212-215.
117. Straub, A., Stasch, J.P., Alonso-Alija, C., Benet-Buchholz, J., Ducke, B., Feurer, A. and Furstner, C., NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett. 2001, 11: 781-784.
118. Strauer, B.E. and Scherpe, A., Ventricular function and coronary hemodynamics after intravenous nitroglycerin in coronary artery disease. Am. Heart J. 1978, 95: 210-219.
119. Sydow, K., Daiber, A., Oelze, M., Chen, Z., August, M., Wendt, M., Ullrich, V., Mulsch, A., Schulz, E., Keaney, J.F., Jr., Stamler, J.S. and Munzel, T., Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J. Clin. Invest. 2004, 113: 482-489.
120. Taylor, A.L., Ziesche, S., Yancy C., Carson, P., D'Agostino, R., Jr., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M. and Cohn, J.N., Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 2004, 351: 2049-2057.
121. Thadani, U., Management of patients with chronic stable angina at low risk for serious cardiac events. Am. J. Cardiol. 1997, 79: 24-30.
122. Thadani, U., Oral nitrates: more than symptomatic therapy in coronary artery disease? Cardiovasc. Drugs Ther. 1997, 11(Suppl 1): 213-218.
123. Thadani, U., Maranda, C.R., Amsterdam, E., Spaccavento, L., Friedman, R.G., Chernoff, R., Zellner, S., Gorwit, J. and Hinderaker, P.H., Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann. Intern. Med. 1994, 120: 353-359.
124. The IONA study group, Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil (IONA) randomised trial. Lancet 2002, 359: 1269-1275.
125. Wainwright, C.L., Miller, A.M., Work, L.M. and Del Soldato, P., NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. Br. J. Pharmacol. 2002, 135: 1882-1888.
126. Wang, B.-Y., Singer, A.H., Tsao, P.S., Drexler, H., Kosek, J. and Cooke, J.P., Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J Am. Coll. Cardiol. 1994, 23: 452-458.
127. Wang, E.Q., Lee, W.I., Brazeau, D. and Fung, H.L., cDNA microarray analysis of vascular gene expression after nitric oxide donor infusions in rats: implications for nitrate tolerance mechanisms. AAPS Pharm Sci. 2002, 4: E10.
128. Wang, E.Q., Lee, W.I. and Fung, H.L., Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice. Br. J. Pharmacol. 2002, 135: 299-302.
129. Wei, E.P., Moskowitz, M.A., Boccalini, P. and Kontos, H.A., Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ. Res. 1992, 70: 1313-1319.
130. Wille, H.H., Sauer, G., Tebbe, U., Neuhaus, K.L. and Kreuzer, H., Nitroglycerin and afterload: effects of aortic compliance and capacity of the Windkessel. Eur. Heart J. 1980, 1: 445-452.
131. Wilson, C., Coldwell, M.C., Hewlett, D.R., Cooper, S.M. and Hamilton, T.C., Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil. Eur. J. Pharmacol. 1988, 152: 331-339.
132. Winbury M.M., Howe, B.B. and Weiss, H.R., Effect of nitroglycerin and dipyridamole on epicardial and endocardial oxygen tension-further evidence for redistribution of myocardial blood flow. J. Pharmacol. Exp. Ther. 1971, 176: 184-199.
133. Wu, C.C., Ko, F.N., Kuo, S.C., Lee, F.Y. and Teng, C.M., YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 1995, 116: 1973-1978.
134. Yusuf, S., MAC Mahon, S., Collins, R. and Peto, R., Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988, 1(8594): 1088-1092.
135. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. and Dagenais, G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000, 342: 145-153.